Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
72% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ICPT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ICPT' s 10-Year Cash to Debt Range
Min: 218.39  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.96
ICPT's Equity to Asset is ranked higher than
95% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ICPT: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
ICPT' s 10-Year Equity to Asset Range
Min: -1.08  Med: 0.58 Max: 0.96
Current: 0.96
-1.08
0.96
Interest Coverage No Debt
ICPT's Interest Coverage is ranked lower than
57% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ICPT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ICPT' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 89.00
M-Score: -2.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -5744.10
ICPT's Operating margin (%) is ranked lower than
89% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. ICPT: -5744.10 )
Ranked among companies with meaningful Operating margin (%) only.
ICPT' s 10-Year Operating margin (%) Range
Min: -6496.56  Med: -1602.79 Max: -766.2
Current: -5744.1
-6496.56
-766.2
Net-margin (%) -5681.55
ICPT's Net-margin (%) is ranked lower than
89% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. ICPT: -5681.55 )
Ranked among companies with meaningful Net-margin (%) only.
ICPT' s 10-Year Net-margin (%) Range
Min: -16258.67  Med: -2981.90 Max: -705.71
Current: -5681.55
-16258.67
-705.71
ROE (%) -41.55
ICPT's ROE (%) is ranked lower than
56% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ICPT: -41.55 )
Ranked among companies with meaningful ROE (%) only.
ICPT' s 10-Year ROE (%) Range
Min: -180.8  Med: -146.09 Max: -91.41
Current: -41.55
-180.8
-91.41
ROA (%) -38.97
ICPT's ROA (%) is ranked lower than
61% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ICPT: -38.97 )
Ranked among companies with meaningful ROA (%) only.
ICPT' s 10-Year ROA (%) Range
Min: -140.05  Med: -98.58 Max: -51.65
Current: -38.97
-140.05
-51.65
ROC (Joel Greenblatt) (%) -2656.12
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ICPT: -2656.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8893.89  Med: -6278.24 Max: -3008.24
Current: -2656.12
-8893.89
-3008.24
» ICPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ICPT Guru Trades in Q3 2014

RS Investment Management 7,016 sh (+118.29%)
Steven Cohen 37,300 sh (+40.75%)
Columbia Wanger 183,300 sh (unchged)
Chuck Royce Sold Out
Andreas Halvorsen Sold Out
» More
Q4 2014

ICPT Guru Trades in Q4 2014

Steven Cohen 300,200 sh (+704.83%)
Columbia Wanger 393,850 sh (+114.87%)
RS Investment Management Sold Out
» More
Q1 2015

ICPT Guru Trades in Q1 2015

Paul Tudor Jones 3,350 sh (New)
Columbia Wanger 315,850 sh (-19.80%)
Steven Cohen 132,300 sh (-55.93%)
» More
Q2 2015

ICPT Guru Trades in Q2 2015

Jim Simons 61,400 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 275,679 sh (-12.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intercept Pharmaceuticals Inc

Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST
According to GuruFocus Insider Data, the largest insider sells during the past week were: Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Target Corp (NYSE:TGT), Aetna Inc (NYSE:AET) and Ross Stores Inc (NASDAQ:ROST). Read more...

Ratios

vs
industry
vs
history
P/B 6.30
ICPT's P/B is ranked lower than
65% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ICPT: 6.30 )
Ranked among companies with meaningful P/B only.
ICPT' s 10-Year P/B Range
Min: 5.27  Med: 13.28 Max: 104.9
Current: 6.3
5.27
104.9
P/S 1509.03
ICPT's P/S is ranked lower than
99% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. ICPT: 1509.03 )
Ranked among companies with meaningful P/S only.
ICPT' s 10-Year P/S Range
Min: 43.77  Med: 1952.19 Max: 5778.25
Current: 1509.03
43.77
5778.25
Current Ratio 31.15
ICPT's Current Ratio is ranked higher than
95% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ICPT: 31.15 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s 10-Year Current Ratio Range
Min: 0.48  Med: 16.38 Max: 31.15
Current: 31.15
0.48
31.15
Quick Ratio 31.15
ICPT's Quick Ratio is ranked higher than
95% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ICPT: 31.15 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s 10-Year Quick Ratio Range
Min: 0.48  Med: 16.38 Max: 31.15
Current: 31.15
0.48
31.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.51
ICPT's Price/Net Cash is ranked higher than
56% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. ICPT: 6.51 )
Ranked among companies with meaningful Price/Net Cash only.
ICPT' s 10-Year Price/Net Cash Range
Min: 7.4  Med: 15.20 Max: 20.35
Current: 6.51
7.4
20.35
Price/Net Current Asset Value 6.43
ICPT's Price/Net Current Asset Value is ranked higher than
52% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. ICPT: 6.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICPT' s 10-Year Price/Net Current Asset Value Range
Min: 7.3  Med: 14.87 Max: 19.86
Current: 6.43
7.3
19.86
Price/Tangible Book 6.31
ICPT's Price/Tangible Book is ranked lower than
57% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. ICPT: 6.31 )
Ranked among companies with meaningful Price/Tangible Book only.
ICPT' s 10-Year Price/Tangible Book Range
Min: 7.27  Med: 14.55 Max: 19.34
Current: 6.31
7.27
19.34
Price/Median PS Value 0.74
ICPT's Price/Median PS Value is ranked higher than
71% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. ICPT: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
ICPT' s 10-Year Price/Median PS Value Range
Min: 0.03  Med: 0.95 Max: 2.11
Current: 0.74
0.03
2.11
Earnings Yield (Greenblatt) (%) -4.14
ICPT's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ICPT: -4.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.51  Med: 0.00 Max: 0
Current: -4.14
-4.51
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 3 52 196
EPS($) -9.33 -10.23 -7.17
EPS without NRI($) -9.33 -10.23 -7.17

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
4 Reasons Intercept Pharmaceuticals Should Be on Your Radar Aug 20 2015
INTERCEPT PHARMACEUTICALS INC Financials Aug 15 2015
Intercept Pharma Dips As Analyst Doubts NASH Market Aug 13 2015
Coverage initiated on Intercept Pharma by Morgan Stanley Aug 13 2015
INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Intercept Pharmaceuticals' Q2 Loss Wider than Expected - Analyst Blog Aug 06 2015
Edited Transcript of ICPT earnings conference call or presentation 5-Aug-15 8:30pm GMT Aug 05 2015
Intercept reports 2Q loss Aug 05 2015
Intercept reports 2Q loss Aug 05 2015
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 05 2015
Intercept Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update Aug 05 2015
Q2 2015 Intercept Pharmaceuticals Inc Earnings Release - After Market Close Aug 05 2015
Intercept Pharmaceuticals (ICPT): Q2 Earnings Preview - Analyst Blog Aug 04 2015
Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming... Jul 29 2015
Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S. Jul 21 2015
Gilead's next target? Jul 09 2015
Intercept Pharmaceuticals Makes a Breakthrough Jul 07 2015
DALCOMP NEGOTIATED CALENDAR Jul 02 2015
The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta -... Jul 02 2015
Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress -... Jul 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK